1. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012; 35:556–564.
2. Ferris FL 3rd, Patz A. Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol. 1984; 28:452–461.
Article
3. Photocoagulation for diabetic macular edema. early treatment diabetic retinopathy study report number 1. early treatment diabetic retinopathy study report number 1. Early treatment diabetic retinopathy study research group. Arch Ophthalmol. 1985; 103:1796–1806.
4. Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol. 1999; 14:223–232.
Article
5. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011; 118:615–625.
6. Diabetic Retinopathy Clinical Research Network. Scott IU, Edwards AR, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007; 114:1860–1867.
Article
7. Avitabile T, Azzolini C, Bandello F, et al. Aflibercept in the treatment of diabetic macular edema: a review and consensus paper. Eur J Ophthalmol. 2017; 27:627–639.
Article
8. Diabetic Retinopathy Clinical Research Network. Aiello LP, et al. Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology. 2011; 118:e5–e14.
Article
9. Sohn HJ, Han DH, Kim IT, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol. 2011; 152:686–694.
Article
10. Jonas JB, Kreissig I, Söfker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol. 2003; 121:57–61.
Article
11. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology. 2004; 111:218–224. discussion 224-5.
12. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010; 117:1134.e3–1146.e3.
Article
13. Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010; 128:289–296.
Article
14. Boyer DS, Yoon YH, Belfort R Jr, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014; 121:1904–1914.
Article
15. Moon BG, Lee JY, Yu HG, et al. Efficacy and safety of a dexamethasone implant in patients with diabetic macular edema at tertiary centers in Korea. J Ophthalmol. 2016; 2016:9810270.
Article
16. Kim TH, Yoon CK, Lee JE, et al. One-year outcome of intravitreal dexamethasone implant for macular edema secondary to central retinal vein occlusion. J Korean Ophthalmol Soc. 2016; 57:1918–1925.
Article
17. Park DH, Ha SJ, Lee SJ. Intraocular pressure elevation after 0.7 mg intravitreal dexamethasone (Ozurdex®) implantation: a one year follow-up. J Korean Ophthalmol Soc. 2015; 56:891–899.
Article
18. Ozkok A, Saleh OA, Sigford DK, et al. THE OMAR STUDY: Comparison of ozurdex and triamcinolone acetonide for refractory cystoid macular edema in retinal vein occlusion. Retina. 2015; 35:1393–1400.
19. Dang Y, Mu Y, Li L, et al. Comparison of dexamethasone intravitreal implant and intravitreal triamcinolone acetonide for the treatment of pseudophakic cystoid macular edema in diabetic patients. Drug Des Devel Ther. 2014; 8:1441–1449.
Article
20. Dutra Medeiros M, Postorino M, Navarro R, et al. Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica. 2014; 231:141–146.
Article
21. Bansal P, Gupta V, Gupta A, et al. Efficacy of ozurdex implant in recalcitrant diabetic macular edema--a single-center experience. Int Ophthalmol. 2016; 36:207–216.
Article
22. Boyer DS, Yoon YH, Belfort R Jr, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014; 121:1904–1914.
Article
23. Callanan DG, Gupta S, Boyer DS, et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology. 2013; 120:1843–1851.
24. Scaramuzzi M, Querques G, Spina CL, et al. Repeated intravitreal dexamethasone implant (Ozurdex) for diabetic macular edema. Retina. 2015; 35:1216–1222.
Article
25. Chou TH, Wu PC, Kuo JZ, et al. Relationship of diabetic macular oedema with glycosylated haemoglobin. Eye (Lond). 2009; 23:1360–1363.
Article
26. Singh RP, Wykoff CC, Brown DM, et al. Outcomes of diabetic macular edema patients by baseline hemoglobin A1c: analyses from VISTA and VIVID. Ophthalmol Retina. 2017; 1:382–388.
27. Pacella F, Ferraresi AF, Turchetti P, et al. Intravitreal injection of ozurdex (R) implant in patients with persistent diabetic macular edema, with six-month follow-up. Ophthalmol Eye Dis. 2016; 8:11–16.
28. Lee H, Kang KE, Chung H, Kim HC. Prognostic factors for functional and anatomic outcomes in patients with diabetic macular edema treated with dexamethasone implant. Korean J Ophthalmol. 2018; 32:116–125.
Article
29. Çevik SG, Yılmaz S, Çevik MT, et al. Comparison of the effect of intravitreal dexamethasone implant in vitrectomized and nonvitrectomized eyes for the treatment of diabetic macular edema. J Ophthalmol. 2018; 2018:1757494.
Article
30. Medeiros MD, Alkabes M, Navarro R, et al. Dexamethasone intravitreal implant in vitrectomized versus nonvitrectomized eyes for treatment of patients with persistent diabetic macular edema. J Ocul Pharmacol Ther. 2014; 30:709–716.
31. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003; 110:681–686.
Article